Ann Intern Med. 10 July 2012.
Patients with diabetes mellitus need information about the effectiveness of innovations in insulin delivery and glucose monitoring.
Purpose: To review how intensive insulin therapy (multiple daily injections [MDI] vs. rapid-acting analogue –based continuous subcutaneous insulin infusion [CSII]) or method of monitoring (self-monitoring of blood glucose [SMBG] vs. real-time continuous glucose monitoring [rt-CGM]) affects outcomes in type 1 and 2 diabetes mellitus.
Data Sources: MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials through February 2012 without language restrictions.
Study Selection: 33 randomized, controlled trials in children or adults that compared CSII with MDI (n = 19), rt-CGM with SMBG (n = 10), or sensor-augmented insulin pump use with MDI and SMBG (n = 4).
Data Extraction: 2 reviewers independently evaluated studies for eligibility and quality and serially abstracted data. Read more